Article Sidebar

Submitted
October 8, 2019
Accepted
October 27, 2019
Published
October 31, 2019
Download
PDF (Bahasa Indonesia)
Statistic
Read Counter : 128 Download : 192

Main Article Content

Abstract

Latar Belakang : Menurut Database GLOBOCAN 2012, kanker prostat merupakan penyebab utama kelima kematian pada pria.(1) Pemahaman tentang peran onkogen dan tumor suppressor genes mendominasi penelitian tentang biologi kanker saat ini dan berpotensi menghasilkan target terapi kanker terbaru. Salah satu perannya pada adenokarsinoma prostat yang masih belum jelas ialah Her-2 dan Ki-67. Perbedaan ekspresi profil molekular Her-2 dan Ki-67 yang diklasifikasikan berdasarkan Gleason grading system terbaru yaitu Grade group diharapkan membantu penentuan prognosis dan manajemen terapi penyakit pada kanker prostat.

Tujuan : Tujuan dari penelitian ini adalah untuk mengetahui korelasi antara ekspresi Her-2 dan Ki-67 dengan Gleason Grade group adenokarsinoma asinar prostat.

Metode: Merupakan penelitian observatif analitik dengan desain cross-sectional menggunakan 31 blok parafin yang terfiksasi formalin dari laboratorium Patologi Anatomik RSUP dr. Kariadi, dengan diagnosis adenokarsinoma asinar prostat kemudian diklasifikasikan menurut kelompok prognostik WHO / ISUP Gleason (Gleason Grade group 1 - 5). Pemeriksaan imunohistokimia dilakukan dengan menggunakan antibodi Her-2 dan Ki-67. Analisa hasil menggunakan uji Spearmans dan uji Kruskal Wallis

Hasil : 31 kasus yang termasuk dalam kriteria inklusi pada penelitian ini, hampir separuhnya (41.94%) termasuk ke dalam Gleason grade group 5. Ekspresi Her-2 positif (+1, +2, +3) hampir didapatkan pada seluruh sampel (90,22%), dengan Her-2 +3 sebagian besar didapatkan pada grade group 5 (71,43%). Ekspresi Ki-67 positif (+1, +2, +3) didapatkan pada seluruh sampel, dengan Ki-67 +3 (>5%) pada Gleason grade group 5 didapatkan sejumlah 5 sampel (38,46%). Pada analisa data dengan uji Spearmans disimpulkan bahwa terdapat korelasi positif antara ekspresi Her-2 dan Ki-67 dengan Gleason Grade group. Pada uji Kruskal Wallis didapatkan perbedaan bermakna antara ekspresi Ki-67 dengan Gleason Grade group.

Kesimpulan: Analisa ekspresi Her-2 dan Ki-67 melalui pemeriksaan imunohistokimia dengan klasifikasi terbaru Gleason Grade group dapat menjadi salah satu parameter prognosis dan manajemen terapi pada adenokarsinoma asinar prostat.

Kata kunci : Adenokarsinoma asinar prostat, Her-2, Ki-67, Gleason Grade group

Keywords

Adenokarsinoma asinar prostat Her-2 Ki-67 Gleason Grade group

Article Details

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
larasati, putri ajeng ayu. (2019). KORELASI ANTARA EKSPRESI Her-2 DAN Ki-67 DENGAN GLEASON GRADE GROUP PADA ADENOKARSINOMA ASINAR PROSTAT. Jurnal Kedokteran Raflesia, 5(1), 39–52. https://doi.org/10.33369/juke.v5i1.9125
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Braga-Basaria M, Dobs A, Muller D, Carducci M, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;3979–3983.
  2. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171–84.
  3. Penyakit Kanker S. InfoDATIN 4 Februari-Hari Kanker Sedunia [Internet]. [cited 2019 Jul 16]. Available from: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf
  4. Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018;12(6):1807–23.
  5. World Health Organization. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. 2016. 138–162 p.
  6. Goldblum JR, Lamps LW, McKenney JK, Myers JL. ROSAI AND ACKERMAN’S SURGICAL PATHOLOGY 11TH EDITION. 11th ed. Philadelphia: Elsevier; 2018. 1494 p.
  7. Ro JY, Shen S, Zhai Q, Ayala A. ADVANCES IN SURGICAL PATHOLOGY PROSTATE CANCER. Cagle P, Allen T, editors. Philadelphia: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2012. 4 p.
  8. Sharifi N, Salmaninejad A, Ferdosi S, Bajestani AN, Khaleghiyan M, Estiar MA, et al. HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method. Oncol Lett [Internet]. 2016 Dec [cited 2018 Sep 8];12(6):4651–8. Available from: https://www.spandidos-publications.com/10.3892/ol.2016.5235
  9. Verma R, Gupta V, Jagjeet S, Monica V, Gopal G, Gupta S, et al. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann [Internet]. 2015;4:488–493. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660702/
  10. Mardiana N, Susilo I. Hubungan Ekspresi Her-2 / Neu , Skor Gleason dan Metastasis Tulang pada Adenokarsinoma Prostat. 2012;22(2):45–50.
  11. Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. Front Oncol [Internet]. 2019 Apr 8 [cited 2019 Jul 9];9:238. Available from: https://www.frontiersin.org/article/10.3389/fonc.2019.00238/full
  12. Zahnd WE, James AS, Jenkins WD, Izadi SR, Fogleman AJ, David ;, et al. Rural-Urban Differences in Cancer Incidence and Trends in the United States. 2017 [cited 2019 Jul 9]; Available from: http://cebp.aacrjournals.org/content/cebp/early/2017/07/27/1055-9965.EPI-17-0430.full.pdf
  13. Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, et al. Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups. Front Med [Internet]. 2017 Sep 29 [cited 2019 Jul 27];4:157. Available from: http://journal.frontiersin.org/article/10.3389/fmed.2017.00157/full
  14. Erickson A, Sandeman K, Lahdensuo K, Taimen P, Rannikko A, Mirtti T. New prostate cancer grade grouping system predicts survival after radical prostatectomy ?. Hum Pathol [Internet]. 2018;75:159–66. Available from: https://doi.org/10.1016/j.humpath.2018.01.027
  15. Yamada Y, Sakamoto S, Shimazaki J, Sugiura M, Amiya Y, Sasaki M, et al. Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis. Prostate Int [Internet]. 2017;5(4):143–8. Available from: https://doi.org/10.1016/j.prnil.2017.03.001
  16. Cheng L, Davidson DD, Lin H, Koch MO. Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy. 2007;(September):6–11.
  17. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006;68(1):110–5.
  18. Kalantari MR, Mahdavi Zafarghandi R, Tavakkoli M, Kalantari S, Aghaee A, Mirsani A, et al. Relation between HER-2 gene expression and prognostic prostate cancer parameters in trus guided biopsies. J Patient Saf Qual Improv. 2019;7(2):69–74.
  19. Signoretti S. Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer. J Natl Cancer Inst. 2000;92(23):1918–25.
  20. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, Kaufman RP, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 1997;79(11):2162–70.
  21. Murray NP, Reyes E, Tapia P, Badínez L, Orellana N. Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications—An Immunocy. Bone Marrow Res. 2012;2012:1–9.
  22. Morote J, De Torres I, Caceres C, Vallejo C, Schwartz S, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer. 1999;84(4):421–5.
  23. Rebbeck TR. Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. [cited 2019 Jul 28]; Available from: www.ebi.ac.uk/gwas/
  24. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. Prostate [Internet]. 2011 Apr [cited 2019 Jul 28];71(5):489–97. Available from: http://doi.wiley.com/10.1002/pros.21265
  25. Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, et al. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS One. 2017;12(11).
  26. Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, et al. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer. 2013;2:271–7.
  27. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol. 2005;18(3):374–81.
  28. Vis AN, Van Rhijn BWG, Noordzij MA, Schröder FH, Van Der Kwast TH. Value of tissue markers p27kip1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002;197(2):148–54.